[go: up one dir, main page]

DE69418744D1 - Verwendung von Pregnanderivaten zur Behandlung von Tumoren - Google Patents

Verwendung von Pregnanderivaten zur Behandlung von Tumoren

Info

Publication number
DE69418744D1
DE69418744D1 DE69418744T DE69418744T DE69418744D1 DE 69418744 D1 DE69418744 D1 DE 69418744D1 DE 69418744 T DE69418744 T DE 69418744T DE 69418744 T DE69418744 T DE 69418744T DE 69418744 D1 DE69418744 D1 DE 69418744D1
Authority
DE
Germany
Prior art keywords
tumors
treatment
derivatives
prognane
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69418744T
Other languages
English (en)
Other versions
DE69418744T2 (de
Inventor
Godefridus Hermanus Jo Deckers
Helenius Jan Kloosterboer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69418744D1 publication Critical patent/DE69418744D1/de
Publication of DE69418744T2 publication Critical patent/DE69418744T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Fats And Perfumes (AREA)
DE69418744T 1993-03-05 1994-03-02 Verwendung von Pregnanderivaten zur Behandlung von Tumoren Expired - Fee Related DE69418744T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93200631 1993-03-05

Publications (2)

Publication Number Publication Date
DE69418744D1 true DE69418744D1 (de) 1999-07-08
DE69418744T2 DE69418744T2 (de) 1999-11-11

Family

ID=8213673

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69418744T Expired - Fee Related DE69418744T2 (de) 1993-03-05 1994-03-02 Verwendung von Pregnanderivaten zur Behandlung von Tumoren

Country Status (14)

Country Link
US (1) US5512556A (de)
EP (1) EP0613687B1 (de)
JP (1) JP3391539B2 (de)
KR (1) KR100312061B1 (de)
AT (1) ATE180669T1 (de)
AU (1) AU671706B2 (de)
CA (1) CA2116829C (de)
DE (1) DE69418744T2 (de)
DK (1) DK0613687T3 (de)
ES (1) ES2134313T3 (de)
GR (1) GR3031114T3 (de)
NO (1) NO307447B1 (de)
NZ (1) NZ260017A (de)
ZA (1) ZA941464B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4334616B2 (ja) * 1994-09-22 2009-09-30 ナームローゼ・フエンノートチヤツプ・オルガノン 湿式粒状化による投与単位体を製造する方法
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
CA2344686C (en) * 1998-10-16 2009-04-28 Akzo Nobel N.V. High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
JP2002541153A (ja) * 1999-04-06 2002-12-03 アクゾ・ノベル・エヌ・ベー 経口活性アンドロゲン
BR0013769A (pt) * 1999-09-06 2002-04-30 Akzo Nobel Nv Esteróides estrogênicos não aromáticos, composição farmacêutica, e, uso de um composto esteróide
ES2241854T3 (es) 2000-07-28 2005-11-01 Akzo Nobel N.V. Estrogenos de sustitucion metilo o etilo en posicion 16 alfa.
ES2284946T3 (es) * 2001-10-18 2007-11-16 Norton Healthcare Limited Formulaciones de tibolona.
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
BR0306789A (pt) * 2002-01-22 2004-12-28 Akzo Nobel Nv Uso de tibolona e método de tratamento de queixas relacionadas com a deficiência do estrogênio em pacientes do sexo feminino
KR20050085024A (ko) * 2002-11-20 2005-08-29 악조 노벨 엔.브이. 티볼론 및 코팅을 포함하는 약학적 정제
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
CN116987680A (zh) * 2022-04-25 2023-11-03 复旦大学 支链氨基酸转氨酶1的功能获得性突变体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3515719A (en) 1967-03-15 1970-06-02 Upjohn Co 7-methyl-6,19-epoxy steroids of the androstane series
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
FR2706454B1 (fr) * 1993-06-17 1995-09-15 Roussel Uclaf Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
ATE180669T1 (de) 1999-06-15
ZA941464B (en) 1994-09-27
KR940021064A (ko) 1994-10-17
KR100312061B1 (ko) 2001-12-28
DE69418744T2 (de) 1999-11-11
JPH072673A (ja) 1995-01-06
CA2116829C (en) 2004-09-14
NO940777D0 (no) 1994-03-04
US5512556A (en) 1996-04-30
JP3391539B2 (ja) 2003-03-31
AU671706B2 (en) 1996-09-05
AU5754294A (en) 1994-09-08
NZ260017A (en) 1997-06-24
EP0613687B1 (de) 1999-06-02
DK0613687T3 (da) 1999-12-06
CA2116829A1 (en) 1994-09-06
NO307447B1 (no) 2000-04-10
NO940777L (no) 1994-09-06
GR3031114T3 (en) 1999-12-31
ES2134313T3 (es) 1999-10-01
EP0613687A1 (de) 1994-09-07

Similar Documents

Publication Publication Date Title
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
TW229156B (de)
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
HU9600834D0 (en) Quinazoline derivatives
TW226375B (de)
ATE193827T1 (de) Verwendung von 1-2-4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
IL175398A0 (en) Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
DE69418744D1 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
GB9302046D0 (en) Antiumoral compound-v
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
GR3036968T3 (en) Adamantyl substituted oxindoles as pharmaceutical agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

8339 Ceased/non-payment of the annual fee